FWBI
Income statement / Annual
Last year (2024), First Wave BioPharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, First Wave BioPharma, Inc.'s net income was -$18.06 M.
See First Wave BioPharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$29.27 K
|
$106.21 K
|
$537.40 K
|
$571.15 K
|
$976.98 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$29.27 K
|
-$106.21 K
|
-$537.40 K
|
-$571.15 K
|
-$976.98 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$903.94 K
|
$5.03 M
|
$691.26 K
|
$38.32 M
|
$19.14 M
|
$8.68 M
|
$4.99 M
|
$2.40 M
|
$2.50 M
|
$1.40 M
|
| General & Administrative Expenses |
$14.72 M
|
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 M
|
$8.24 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
-$29.27 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.72 M
|
$10.71 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 M
|
$8.24 M
|
$7.69 M
|
$4.13 M
|
$3.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$529.10 K
|
$211.43 K
|
$0.00
|
$210.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.62 M
|
$15.74 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14.74 M
|
$13.43 M
|
$10.08 M
|
$6.63 M
|
$4.73 M
|
| Cost And Expenses |
$0.00
|
$15.77 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14.74 M
|
$13.43 M
|
$10.08 M
|
$6.63 M
|
$4.73 M
|
| Interest Income |
$0.00
|
$19.93 K
|
$8.42 K
|
$1.17 K
|
$484.00
|
$433.94
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$875.00
|
$0.00
|
$15.88 K
|
$11.24 K
|
$5.84 M
|
$433.94 K
|
$101.85 K
|
$875.20 K
|
$5.94 M
|
$1.59 M
|
| Depreciation & Amortization |
$0.00
|
$29.27 K
|
-$195.06 K
|
$3.42 M
|
$777.26 K
|
$1.02 M
|
$798.45 K
|
$754.00 K
|
$734.50 K
|
$733.60 K
|
| EBITDA |
-$15.62 M |
-$15.74 M |
-$12.87 M |
-$55.63 M |
-$25.66 M |
-$13.72 M |
-$12.63 M |
-$9.33 M |
-$5.89 M |
-$4.00 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.44 M
|
-$24.15 K
|
-$1.95 M
|
-$1.83 M
|
-$6.24 M
|
-$433.94 K
|
-$311.85 K
|
-$875.20 K
|
-$8.27 M
|
-$1.20 M
|
| Income Before Tax |
-$18.06 M
|
-$15.79 M
|
-$14.63 M
|
-$58.54 M
|
-$32.67 M
|
-$15.18 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$1.95 M
|
$540.34 K
|
$6.05 M
|
$433.94 K
|
-$108.15 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$18.06 M
|
-$15.79 M
|
-$16.58 M
|
-$59.08 M
|
-$38.72 M
|
-$15.61 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.33 |
-46.96 |
-461.72 |
-27799.23 |
-57194.08 |
-29238.43 |
-1840.81 |
-2192.53 |
-4711.55 |
-1293.12 |
| EPS Diluted |
-5.33 |
-46.96 |
-461.72 |
-27799.23 |
-57194.08 |
-29238.43 |
-1840.81 |
-2192.53 |
-4711.55 |
-1261.75 |
| Weighted Average Shares Out |
$3.43 M
|
$336.34 K
|
$35.91 K
|
$2.13 K
|
$677.05
|
$533.94
|
$7.35 K
|
$5.06 K
|
$3.10 K
|
$4.59 K
|
| Weighted Average Shares Out Diluted |
$3.43 M
|
$336.34 K
|
$35.91 K
|
$2.13 K
|
$677.05
|
$533.94
|
$7.35 K
|
$5.06 K
|
$3.10 K
|
$4.70 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
